Fulcrum Asset Management LLP purchased a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) during the third quarter, Holdings Channel reports. The firm purchased 20,164 shares of the company’s stock, valued at approximately $803,000.
Several other hedge funds have also recently added to or reduced their stakes in the company. Cornerstone Planning Group LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after purchasing an additional 755 shares in the last quarter. Root Financial Partners LLC bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at about $33,000. Western Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at about $43,000. Sunbelt Securities Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at about $45,000. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Teva Pharmaceutical Industries by 64.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock valued at $50,000 after buying an additional 647 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.
Teva Pharmaceutical Industries Stock Performance
NYSE TEVA opened at $43.52 on Friday. The company has a 50-day simple moving average of $40.00 and a two-hundred day simple moving average of $35.01. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 1.59. Teva Pharmaceutical Industries Ltd. has a 12-month low of $24.01 and a 12-month high of $44.31. The firm has a market cap of $50.72 billion, a price-to-earnings ratio of 101.22, a PEG ratio of 4.05 and a beta of 0.97.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.72 by $0.14. The firm had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The company’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.78 earnings per share. On average, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current year.
Insider Activity at Teva Pharmaceutical Industries
In related news, EVP Richard Daniell sold 20,003 shares of the firm’s stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $42.80, for a total transaction of $856,128.40. Following the transaction, the executive vice president directly owned 55,755 shares in the company, valued at $2,386,314. This trade represents a 26.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian Savage sold 7,342 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the transaction, the insider directly owned 8,500 shares in the company, valued at $330,225. This trade represents a 46.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 715,945 shares of company stock worth $29,061,351 over the last three months. Corporate insiders own 0.54% of the company’s stock.
Recent Teva Pharmaceutical Industries Headlines
Investors following TEVA have been watching these headlines:
- Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and reiterated an Overweight rating, signaling confidence in further upside. Piper Sandler analyst ratings
- Neutral Sentiment: Healthcare stocks broadly declined Wednesday afternoon, a sector headwind that may have affected trading but does not reflect Teva-specific fundamentals. Healthcare sector update
- Negative Sentiment: CEO Richard Francis sold 250,000 shares for about $10.6 million, reducing his stake by 21.23%. EVP Richard Daniell also sold 20,003 shares and 25,000 shares in separate transactions. These sizable insider sales may raise concerns about executive confidence, although the filings do not state the reasons for the transactions. CEO SEC filing EVP SEC filing
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on TEVA shares. Weiss Ratings upgraded Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, November 4th. UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research report on Friday, September 4th. TD Cowen increased their price target on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Leerink Partners lifted their price target on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Finally, Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an “overweight” rating in a report on Thursday. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.15.
Read Our Latest Stock Report on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
See Also
- Five stocks we like better than Teva Pharmaceutical Industries
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
